MiNK Therapeutics will announce Q3 2025 financial results on November 14, discussing recent clinical advancements and future milestones.
Quiver AI Summary
MiNK Therapeutics, Inc. announced that it will release its third quarter 2025 financial results on November 14th, prior to the market opening. This follows the company's presentation at the 2025 Society for Immunotherapy of Cancer Annual Meeting, where promising clinical data for its agenT-797 iNKT cell therapy was shared, showing durable immune reconstitution in patients with advanced solid tumors. Executives will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the financial results, recent clinical advancements, including the SITC findings, and future corporate milestones. MiNK is focused on developing allogeneic iNKT cell therapies for cancer and immune disorders, with a goal of creating scalable and effective treatments.
Potential Positives
- Announcement of Q3 2025 financial results scheduled for November 14th indicates transparency and commitment to keeping investors informed.
- Positive new clinical data from the company’s agenT-797 iNKT cell therapy presented at a significant industry conference demonstrates promising immune reconstitution and activity in advanced solid tumor patients.
- The upcoming conference call will provide an opportunity for executives to discuss financial results and clinical progress, enhancing investor engagement and confidence.
- MiNK's innovative iNKT platform and pipeline suggest strong potential for the development of novel therapies in treating various serious health conditions.
Potential Negatives
- Upcoming financial results announcement may indicate a lack of immediate progress or transparency regarding the company's financial health, which could negatively impact investor confidence.
- The focus on clinical data presentation suggests that the company is still heavily reliant on the development of unproven therapies, which may be perceived as a high-risk strategy for investors.
- Forward-looking statements may raise concerns about the company's ability to deliver safety and efficacy, as they acknowledge inherent risks and uncertainties associated with their product development.
FAQ
When will MiNK’s Q3 2025 financial results be released?
MiNK Therapeutics will release its third quarter 2025 financial results on November 14, 2025, before the market opens.
What is iNKT cell therapy?
iNKT cell therapy is an innovative treatment using invariant natural killer T cells to target cancer and immune disorders.
How can I access the conference call?
The conference call can be accessed by dialing (646) 307-1963 or (800) 715-9871 with Conference ID: 3474114.
What data will be discussed during the conference call?
The call will cover financial results, recent clinical progress, and new data presented at the SITC Annual Meeting.
Where can I find the webcast replay?
The webcast and replay will be available on the Events & Presentations page of MiNK's website after the event.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$INKT Hedge Fund Activity
We have seen 1 institutional investors add shares of $INKT stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LONGBOW FINANCE SA removed 16,667 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $123,129
- OSAIC HOLDINGS, INC. added 144 shares (+inf%) to their portfolio in Q2 2025, for an estimated $1,063
- COVESTOR LTD added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
- JONES FINANCIAL COMPANIES LLLP added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
- GAME PLAN FINANCIAL ADVISORS, LLC added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$INKT Analyst Ratings
Wall Street analysts have issued reports on $INKT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/15/2025
To track analyst ratings and price targets for $INKT, check out Quiver Quantitative's $INKT forecast page.
Full Release
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that the Company will release its third quarter 2025 financial results before the market opens on Friday, November 14th.
The announcement follows MiNK’s late-breaking presentation at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting, where new clinical data from the company’s agenT-797 iNKT cell therapy demonstrated durable immune reconstitution and signals of activity in patients with advanced solid tumors.
MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss financial results, recent clinical progress including SITC data, and upcoming corporate milestones.
Conference Participant Dial Information
United States - New York (646) 307-1963
USA & Canada - Toll-Free (800) 715-9871
Conference ID: 3474114
Webcast & Replay Information
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website following the event.
Live event link:
https://edge.media-server.com/mmc/p/4bufw45x
Webcast Replay:
https://investor.minktherapeutics.com/events-and-presentations
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. MiNK’s proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse.
Its lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. MiNK’s pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential, safety, clinical benefit, and development plans for agenT-797 and other iNKT-based therapies. These statements involve risks and uncertainties, including those described under “Risk Factors” in MiNK’s most recent SEC filings. MiNK undertakes no obligation to update these statements except as required by law.
Contacts
Investor Contact: 917-362-1370 |
[email protected]
Media Contact: 781-674-4428 |
[email protected]
Source: MiNK Therapeutics
